Paul S. Ritch

6.2k citations

133 papers · 4.6k indexed · 2 hit papers · h-index 38

Impact in

Oncology top 0.5%
- Pancreatic and Hepatic Oncology Research
Otorhinolaryngology top 2%

Papers in

Oncology 92
- Pancreatic and Hepatic Oncology Research 58
- Colorectal Cancer Treatments and Studies 16
- Cancer Treatment and Pharmacology 10
Cancer Research 29
- Cancer Genomics and Diagnostics 25

Co-authors: Bradley A. Erickson Tom Anderson Douglas B. Evans Susan Tsai Kathleen K. Christians Ben George Richard M. Hansen Edward J. Quebbeman
Journals: Journal of Clinical Oncology (30 papers)Surgery (11 papers)Cancer (10 papers)Annals of Oncology (9 papers)Journal of Gastrointestinal Surgery (5 papers)
Partner nations: United States Spain United Kingdom

In The Last Decade

Paul S. Ritch

131 papers receiving 4.4k citations

Hit Papers

align trajectories log scale

HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma 2017 · 365 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 Journal of Clinical Oncology
2009 Journal of Clinical Oncology

Peers

Countries citing papers authored by Paul S. Ritch

Since Specialization

Citations

This map shows the geographic impact of Paul S. Ritch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul S. Ritch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul S. Ritch more than expected).

Fields of papers citing papers by Paul S. Ritch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul S. Ritch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul S. Ritch. The network helps show where Paul S. Ritch may publish in the future.

Co-authors

The 25 scholars most cited alongside Paul S. Ritch, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Paul S. Ritch Line = papers co-authored together Paul S. Ritch links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer Surgery ·Chad A. Barnes, Mohammed Aldakkak, Kathleen K. Christians, Callisia N. Clarke, Kulwinder S. Dua, Ben George, Paul S. Ritch, Mandana Kamgar, William A. Hall, Naveen M. Kulkarni, Bradley A. Erickson, Douglas B. Evans, Susan Tsai	2020	15
2	Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer HPB ·Ashley N. Krepline, Jennifer L. Geurts, Oscar E. B. M Silva, Kathleen K. Christians, Callisia N. Clarke, Ben George, Paul S. Ritch, Abdul H. Khan, William A. Hall, Bradley A. Erickson, Mike Griffin, Douglas B. Evans, Susan Tsai	2020	2
3	Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery Surgery ·Chad A. Barnes, Mariana Chávez, Susan Tsai, Mohammed Aldakkak, Ben George, Paul S. Ritch, Kulwinder S. Dua, Callisia N. Clarke, Parag Tolat, Catherine E. Hagen, William A. Hall, Bradley A. Erickson, Douglas B. Evans, Kathleen K. Christians	2019	46
4	HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma Journal of Clinical Oncology ·Sunil R. Hingorani, Lei Zheng, Andrea J. Bullock, Tara Elisabeth Seery, William Proctor Harris, Darren Sigal, Fadi Braiteh, Paul S. Ritch, Mark M. Zalupski, Nathan Bahary, Paul E. Oberstein, Andrea Wang‐Gillam, Wilson Wu, Dimitrios Chondros, Ping Jiang, Sihem Khelifa, Jie Pu, Carrie Aldrich, Andrew Hendifar Hit paper breakdown →	2017	365
5	Randomized phase 2 study of PEGPH20 Plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA) Annals of Oncology ·Sunil R. Hingorani, Andrea J. Bullock, Tara Elisabeth Seery, Lei Zheng, Darren Sigal, Paul S. Ritch, Fadi S. Braiteh, Mark M. Zalupski, Nathan Bahary, William Proctor Harris, Jeffrey J. Pu, Carrie Aldrich, Sihem Khelifa, Wilson Wu, Dimitrios Chondros, Ping Jiang, Andrew Hendifar	2017	4
6	Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy? Journal of Gastrointestinal Surgery ·Chad A. Barnes, Ashley N. Krepline, Mohammed Aldakkak, Callisia N. Clarke, Kathleen K. Christians, Abdul H. Khan, Bryan Hunt, Paul S. Ritch, Ben George, William A. Hall, Bradley A. Erickson, Douglas B. Evans, Susan Tsai	2017	23
7	PEGPH20 improves pfs in patients with metastatic pancreatic ductal adenocarcinoma: A randomized phase 2 study in combination with nab-paclitaxel/gemcitabine Annals of Oncology ·Sunil R. Hingorani, Andrea J. Bullock, Tara Elisabeth Seery, Lei Zheng, Darren Sigal, Paul S. Ritch, Fadi Braiteh, Mark M. Zalupski, Nathan Bahary, William Proctor Harris, Jie Pu, Carrie Aldrich, Sihem Khelifa, Wilson Wu, Joaquina Baranda, Ping Jiang, Andrew Hendifar	2017	5
8	Poor Glycemic Control Is Associated with Failure to Complete Neoadjuvant Therapy and Surgery in Patients with Localized Pancreatic Cancer Journal of Gastrointestinal Surgery ·Lene Buhl Riis, Kathleen K. Christians, Mohammed Aldakkak, Ashley N. Krepline, Paul S. Ritch, Ben George, Bradley A. Erickson, W. Dennis Foley, Philip J. Finnegan, Douglas B. Evans, Susan Tsai	2016	9
9	Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy Surgery ·Kathleen K. Christians, W. Schroers, Ben George, Paul S. Ritch, Bradley A. Erickson, Fabian M. Johnston, Parag Tolat, W. Dennis Foley, Douglas B. Evans, Susan Tsai	2015	90
10	Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer HPB ·Mohammed Aldakkak, Kathleen K. Christians, Ashley N. Krepline, Ben George, Paul S. Ritch, Bradley A. Erickson, Fabian M. Johnston, Douglas B. Evans, Susan Tsai	2015	52
11	Patency Rates of Portal Vein/Superior Mesenteric Vein Reconstruction After Pancreatectomy for Pancreatic Cancer Journal of Gastrointestinal Surgery ·Ashley N. Krepline, Kathleen K. Christians, А В Фаустов, 王荣花, Paul S. Ritch, Ben George, Bradley A. Erickson, W. Dennis Foley, Edward J. Quebbeman, Kiran K. Turaga, Fabian M. Johnston, T. Clark Gamblin, Douglas B. Evans, Susan Tsai	2014	35
12	Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer Annals of Oncology ·Brian M. Wolpin, Eileen M. O’Reilly, Yoo-Joung Ko, Lawrence S. Blaszkowsky, Mark U. Rarick, Caio Rocha‐Lima, Paul S. Ritch, Emily Chan, Jennifer L. Spratlin, Teresa Macarulla, Elaine McWhirter, Denis Pezet, Mikhail Lichinitser, Laslo Roman, Alan C. Hartford, Kendall Morrison, Agus Suhariono, M. Vincent, Leonard Reyno, Manuel Hidalgo	2013	29
13	Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma Annals of Oncology ·Al B. Benson, Edith P. Mitchell, Neil Abramson, Barbara Klencke, Paul S. Ritch, Karol Basiński, Mary Bagenal, Tab Bonny, Jeremey Levin, John Hohneker	2002	12
14	Hematologic and Immunologic Evaluation of Recombinant Human Interleukin-6 in Patients with Advanced Malignant Disease: Evidence for Monocyte Activation Journal of Immunotherapy ·Carolyn A. Keever-Taylor, Patricia L. Witt, R L Truitt, Hervé Riou, Ernest C. Borden, Paul S. Ritch	1996	15
15	Quantitation of ineterferon-induced Mx protein in whole blood lysates by an immunochemiluminsescent assay: elimination of protease activity of cell lysates in toto Journal of Immunological Methods ·Se‐Kyung Oh, Stefan Luhowskyj, XU Da-hua, Paul S. Ritch, Dirk J. Reitsma, Harry Towbin, Michel A. Horisberger, Peter von Wussow, Barry Bluestein	1994	21
16	Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. PubMed ·Patricia L. Witt, Paul S. Ritch, Douglas Reding, Timothy L. McAuliffe, Ligia T. Domenech, Sidney E. Grossberg, Ernest C. Borden	1993	65
17	Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. Journal of Clinical Oncology ·Howard S. Höchster, K M Kim, Drona Bandyopadhyay, R B Mann, Richard S. Neiman, Martin M. Oken, Peter A. Cassileth, Phillip B. Stott, Paul S. Ritch, M J O'Connell	1992	139
18	Imaging of Regional Spread of Breast Cancer by Internal Mammary Lymphoscintigraphy, CT, and MRI Clinical Nuclear Medicine ·Halil Turgut Turoğlu, Nora A. Janjan, Michael Thorsen, D. Sänger, Paul S. Ritch, Richard M. Hansen, リチャードローレン, Власкина Татьяна Юрьевна, B. David Collier	1992	4
19	Continuous 5-Fluorouracil Infusion and Alpha Interferon in Advanced Cancers: A Report of Initial Treatment Results The American Journal of the Medical Sciences ·Richard M. Hansen, Paul S. Ritch, Joseph A. Libnoch, Tom Anderson	1991	7
20	Phase II Trial of Methylglyoxal-Bis (guanylhydrazone) (MGBG) in Patients with Refractory Multiple Myeloma: An Eastern Cooperative Oncology Group (ECOG) Study Cancer Investigation ·Jane N. Winter, Paul S. Ritch, Steven T. Rosen, Martin M. Oken, Janet Wolter, Peter H. Wiernik, Michael J. O’Connell	1990	1

About Paul S. Ritch

Paul S. Ritch is a scholar working on Oncology, Cancer Research, Genetics, Pulmonary and Respiratory Medicine and Hematology, having authored 133 papers that have together received 4.6k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (58 papers), Cancer Genomics and Diagnostics (25 papers), Colorectal Cancer Treatments and Studies (16 papers), Renal cell carcinoma treatment (15 papers), Neuroendocrine Tumor Research Advances (13 papers), Lymphoma Diagnosis and Treatment (12 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Cancer Treatment and Pharmacology (10 papers). The work is most often cited by research in Oncology (2.9k citations), Otorhinolaryngology (237 citations), Pulmonary and Respiratory Medicine (1.7k citations), Cancer Research (720 citations) and Genetics (322 citations). Paul S. Ritch has collaborated with scholars based in United States, Spain and United Kingdom. Frequent co-authors include Bradley A. Erickson, Tom Anderson, Douglas B. Evans, Susan Tsai, Kathleen K. Christians, Ben George, Richard M. Hansen, Edward J. Quebbeman, Parag Tolat and Kenneth R. Hande. Their work appears in journals such as Journal of Clinical Oncology, Surgery, Cancer, Annals of Oncology and Journal of Gastrointestinal Surgery.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact